January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
time to read: 2 minutes
|
Author:
Carsten Mainitz
ISIN:
SG2E73981531 , NL0015436031 , US60770K1079
Table of contents:
Author
Carsten Mainitz
The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.
Tag cloud
Shares cloud
CUREVAC NV - Approval expected by the beginning of the second quarter
While vaccines from BioNTech and Moderna are now being administered in Germany, Tübingen-based CureVac takes further necessary steps towards the product's approval. Yesterday, CureVac reported that preclinical data from the Covid-19 vaccine candidate CVnCoV confirmed the induction of a distinct immune response in non-human primates. In the study, the vaccine was tested in rhesus macaques with two vaccinations within 28 days.
"The complete protection of the lungs of vaccinated animals demonstrates the potential of CVnCoV to protect humans from the devastating effects of the virus. We are very encouraged that CVnCoV is effective at a low dose. The amount is even lower than the dose we are currently testing with in the pivotal clinical trial," stated Dr. Mariola Fotin-Mleczek, Chief Technology Officer of the Company.
The Company plans to complete the final Phase 3 in the first quarter and expects approval no later than the second quarter's beginning. The advantage of the CureVac vaccine is that it can be stored at refrigerator temperature for three months. With the products currently available, these are only a few days or weeks. The Tübingen-based Company plans to sell 300 million doses of the vaccine in 2021. The EU has already ordered 225 million doses.
At a current share price of around USD 103, the Company is valued at EUR 14 billion market capitalization. Analyst estimates are that the Group will generate EUR 1.5 billion in sales in the current year and EUR 2.5 billion in 2022. If analysts are to be believed, the share is currently too expensive. On average, the experts' target price is USD 72. Stock exchange trades the future. We are curious.
Q&M DENTAL GROUP - facing a revaluation
Singapore-based Q&M Dental Group is a leading private dental provider in Asia. The Group owns the largest network of 114 practices in the island nation and operates in Malaysia and China. Q&M was founded in 1996 and has established itself as a renowned, high-quality brand.
In addition to this bread-and-butter business, Q&M is building a new division that should lead to the Company's revaluation. In September, it was announced that the Ministry of Health licensed its 51% subsidiary, Acumen Diagnostics Pte, to offer clinical laboratory testing for SARS CoV-2 RNA. Q&M expects strong growth with very high margins. Another new revenue stream is the sale of a proprietary Corona test. It has already been sold to Malaysia and Indonesia. We estimate each order to be worth 5 million units or more. More countries will likely turn to Q&M's products.
When converted, the profitable Company is valued at EUR 280 million. Given the considerable potential in the "Corona business," a revaluation of the Company should occur soon.
MODERNA INC - Vaccine available in Germany since yesterday
A second Corona vaccine has been available in Germany since yesterday. The US manufacturer Moderna delivered 63,600 vaccine doses to a central depot in the district of Osnabrück. Moderna has long focused on the discovery and development of messenger RNA (mRNA) based drugs.
While BioNTech's vaccine must be stored and transported at minus 70 degrees, Moderna's vaccine doses can be stored at just minus 20 degrees and have a much longer shelf life at refrigerator temperatures than its competitor.
At the current USD 118 per share, the Massachusetts-based biotechnology Company is valued at USD 45 billion. The average price target of analysts following the stock is USD 135.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
